EGFR and neoplasm: Anti-EGFR inhibitor-induced upregulation of MHC class I/II expression as well as the inactivation of GSK-3β/FoxP3 dampens Treg function and increases CTL activity is known as the main event that explains the modulation of the tumor immune microenvironment by cetuximab.